3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
94
Neoplasm Metastasis
9
Prostatic Neoplasms, Castration-Resistant
5
Breast Neoplasms
3
Neoplasms
2
Metastatic Castration Resistant Prostate Cancer
2
Castration-resistant Prostate Cancer
2
Urinary Bladder Neoplasms
1
Stage II Prostate Adenocarcinoma
1
Salivary Glands Tumors
1
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
1
Prostate Cancer Metastatic
1
Prostate Adenocarcinoma
1
Pharmacogenetic Study
1
Oligometastatic Prostate Carcinoma
1
Neoadjuvant Therapy
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
Metastatic Hormone Refractory Prostate Cancer
1
Metastatic Castration-resistent Prostate Cancer
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
Metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-Resistant Prostate Cancer
1
Dementia
1
Cushing Syndrome
1
Cognitive Dysfunction
1
Castrate-resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Cancer Pain
1
Adrenocortical Carcinoma
1
Adenocarcinoma
1
Interventions
radium Ra 223 dichloride
1
niraparib
1
enzalutamide
1
darolutamide
1
capivasertib
1
cabazitaxel
1
apalutamide
1
abiraterone
1
Solutions
1
Prednisone
1
Injections
1
Docetaxel
1
Carboplatin
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Metastatic Castration-resistant Prostate Cancer (mCRPC)
×
Abiraterone Acetate
×
Clear all
NCT03903835
2025-04-09
ProBio
Karolinska Institutet
Phase 3
Recruiting
750 enrolled